Skip to main content

Table 1 Baseline characteristics of the 35 participants who completed the study

From: A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers

  All (n = 35) Walk (n = 21) Strength-Walk (n = 14)
Demographic and general characteristics
 Male gendera 26 (74%) 12 (57%)a 14 (100%)a
 Age (years, median, Q1-Q3) 48 (44–54) 48 (43–54) 49 (44–54)
 Caucasian race 35 (100%) 21 (100%) 14 (100%)
 BMI (Kg/m2) 25.6 (22.2-27.2) 25.3 (21.6-27.5) 25.8 (24.1-26.9)
Risk Group
 Ex-intravenous drug users 8 (23%) 7 (33%) 1 (7%)
 Men-having-sex-with-men 21 (57%) 7 (33%) 13 (93%)
 Heterosexual infection 6 (17%) 6 (29%) 0
 Vertical infection 1 (3%) 1 (5%) 0
HIV infection variables
 Previous AIDS-defining events 9 (25%) 7 (33%) 2 (14%)
 Nadir CD4+ T-cells/μL (median, Q1-Q3) 94 (37–197) 80 (34–140) 188 (77–258)
 Current CD4+ T-cells/μL (median, Q1-Q3) 577 (406–726) 485 (374–686) 624 (527–740)
 VL < 40 c/mL 34 (97%) 21 (100%) 13 (93%)
 Hepatitis C virus coinfection 4 (11%) 4 (19%) 0
 VACS Index 12 (5–19) 16 (6–24) 9 (0–12)
Smoking and Treatments
 Smokers 8 (23%) 6 (29%) 2 (14%)
 2NRTI + Protease inhibitor 14 (40%) 7 (33%) 7 (50%)
 2NRTI + NNRTI 11 (31%) 7 (33%) 4 (29%)
 Other ART regimens 10 (28%) 7 (33%) 3 (21%)
 Beta blockersb 6 (17%) 5 (24%) 1 (7%)
 Other anti-hypertensive drugsb 5 (14%) 2 (10%) 3 (21%)
 Statinsb 10 (29%) 4 (19%) 6 (42%)
 Fibratesb 2 (6%) 0 2 (14%)
Inclusion Criteria
 Lipodystrophy 35 (100%) 21 (100%) 14 (100%)
  ≥ 1 metabolic syndrome criterion 32 (91%) 19 (90%) 13 (93%)
 Blood triglycerides ≥150 mg/dL 14 (40%) 8 (38%) 6 (42%)
 Blood HDL-C ≤40 (m) or ≤50 (w) mg/dL 12 (34%) 9 (43%) 3 (21%)
 Blood glucose ≥110 mg/dL 1 (3%) 0 1 (7%)
 Waist ≥102 (m) or ≥88 (w) cm 10 (28%) 8 (38%) 2 (14%)
 SBP ≥150 or DBP ≥85 mmHg 12 (34%) 7 (33%) 5 (36%)
  1. Values are expressed as number of patients (%) where no otherwise indicated
  2. aWalk vs. strength-walk, p = 0.005
  3. bChronic treatment, with no changes during the training period or the 6 weeks before training
  4. VACS Veterans Ageing Cohort Study, NRTI nucleoside reverse transcriptase inhibitors, NNRTI non-nucleoside reverse transcriptase inhibitors, m men, w women, SBP systolic blood pressure, DBP, diastolic blood pressure